<DOC>
	<DOCNO>NCT01361217</DOCNO>
	<brief_summary>Inhibitory drug-drug interaction ( DDIs ) considerable concern inhibition drug 's clearance lead increase plasma concentration subsequent adverse event toxicity . Fluoxetine ( Prozac® ) widely prescribe antidepressant , also potent inhibitor cytochrome P450 ( CYP ) enzymes . Fluoxetine choose model inhibitor study clinically important inhibitor multiple CYP enzymes vary potency isoform . From vitro data , fluoxetine predict moderate inhibitor CYP2D6 , strong inhibitor CYP2C19 CYP3A4 . However , vivo fluoxetine cause potent interaction CYP2D6 weak-to-no interaction CYP3A4 . The magnitude vivo interaction fluoxetine CYP2C19 know . This vitro-to-in vivo discrepancy concern two reason : 1 ) In clinical drug development , vivo drug-drug interaction test vitro experiment predict risk vivo DDIs 2 ) Because vivo DDI 's test use rank order approach go potent vitro interaction least potent interaction vivo observe . In study interaction fluoxetine CYP3A4 , CYP2C19 CYP2D6 quantify simultaneously quantitative vitro-to-in vivo prediction test . Fluoxetine orally administer daily 14 day CYP1A2 , CYP3A4 , CYP2C19 CYP2D6 activity test end fluoxetine dose use cocktail CYP probe include caffeine , midazolam , omeprazole dextromethorphan . Lovastatin administered separate day use second CYP3A4 probe test whether CYP3A4 inhibition fluoxetine depend contribution intestinal CYP3A4 probe clearance . Plasma urine sample collect 12 24 hr , respectively , control session ( fluoxetine administration ) 24 hrs treatment session ( fluoxetine multiple dose ) . The concentration probe drug metabolite ( applicable ) well fluoxetine metabolite measure collected sample pharmacokinetic analysis perform . The primary outcome measure CYP inhibition increase area plasma concentration time curve ( AUC ) probes.The null hypothesis study area plasma concentration time curve ( AUCs ) caffeine , dextromethorphan , omeprazole , midazolam lovastatin control session fluoxetine session . Because lovastatin great variability baseline pharmacokinetics study power base specific null hypothesis lovastatin . The alternative hypothesis fluoxetine decrease clearance probe drug result significant increase AUCs control study session .</brief_summary>
	<brief_title>The Effects Multiple Dose Fluoxetine Metabolites CYP1A2 , CYP2C19 , CYP2D6 CYP3A4 Activity</brief_title>
	<detailed_description />
	<mesh_term>Fluoxetine</mesh_term>
	<criteria>Subjects must 1850 year old . Subjects must currently good health normal gastrointestinal heart function ( determined medical history ) Laboratory value indicate normal liver ( Serum Albumin 3.9 5.0 g/dL , Total Bilirubin &lt; 1.4mg/dL , Alanine Transaminase 9 60 IU/L Aspartate Transaminase 10 40 IU/L ) kidney ( Serum Creatinine &lt; 1.5 mg/dL Blood Urea Nitrogen 7 20 mg/dL ) function well normal blood glucose value ( Fasting Blood Glucose &lt; 100 mg/dL ) . Subjects must know allergy fluoxetine selective serotonin reuptake inhibitor ( SSRIs ) , monoamine oxidase inhibitor ( MAOIs ) , benzodiazepine drug , caffeine , omeprazole , dextromethorphan , lovastatin chemically related drug . Women childbearing age must willing use measure avoid conception study period willing pregnancy test Study Days 1 16 . Subjects must agree take know substrate , inhibitor , inducer activators ofcyrochrome P450 ( CYP ) CYP1A2 , CYP3A4 , CYP2C19 CYP2D6 two week start study three week last day study . This list include restrict antidepressant antipsychotic agent , azole antifungal agent , macrolide antibiotic , antiepileptic medication , antihypertensive agent cholesterol lower agent . They must also willing avoid ingest grapefruit , grapefruit juice grapefruit containing product , herbalbased nutrient supplement medication period time . Use oral contraceptive permit . Subjects must willing avoid caffeinecontaining food , beverage , dietary supplement 24 hr prior throughout study session avoid alcohol 48 hr prior throughout study session . Subjects must willing avoid heavy exercise study Current cigarette smoker History liver , kidney , gastrointestinal heart disease Lab test result indicative abnormal liver kidney function , diabetes ( see inclusion criterion ) . Allergy monoamine oxidase inhibitor ( MAOIs ) chemically relate drug benzodiazepine drug Prior experience side effect fluoxetine selective serotonin reuptake inhibitor ( SSRIs ) CYP2D6 CYP2C19 poor metabolizer genotype CYP3A5 expressor genotype Recent ingestion ( &lt; 2 week ) medication know metabolized alter CYP1A2 , CYP3A4 , CYP2C19 CYP2D6 activity A positive pregnancy test breastfeed History diabetes , peptic ulcer inflammatory bowel disease Overweight ; body mass index ≥ 30 underweight ; body mass index ≤ 18 Use chronic prescription overthecounter medication ( except oral contraceptive ) Use antidepressant last two week precede study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Fluoxetine</keyword>
	<keyword>CYP3A4</keyword>
	<keyword>CYP2D6</keyword>
	<keyword>CYP2C19</keyword>
	<keyword>Drug-Drug Interaction</keyword>
	<keyword>Multi-CYP Inhibition</keyword>
</DOC>